NCT00347711
Withdrawn
Phase 3
Bevacizumab and Retinal Vascular Occlusions
Asociación para Evitar la Ceguera en México1 site in 1 countryJune 2006
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Edema Macular
- Sponsor
- Asociación para Evitar la Ceguera en México
- Locations
- 1
- Status
- Withdrawn
- Last Updated
- last year
Overview
Brief Summary
To evaluate the effects of Intravitreal Bevacizumab in macular edema in retinal vascular occlusion.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Vascular occlusion and edema macular diagnosticated by fluorescein angiography and coherent optic tomography
Exclusion Criteria
- •Previous surgery
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein OcclusionMacular EdemaRetinal Vein OcclusionNCT00970957Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA107
Terminated
Phase 4
Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVOMacular EdemaCentral Retinal Vein OcclusionNCT00566761Asociación para Evitar la Ceguera en México10
Unknown
Not Applicable
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.NCT01707745Sivakami A Pai50
Recruiting
Not Applicable
Treatment with bevacizumab for ocular vascular lesionsOcular vascular lesionsJPRN-UMIN000020916Keio University, School of Medicine1,000
Completed
Not Applicable
Bevacizumab Treatment and Retinal Vessel MonitoringCancerNCT00740168Technische Universität Dresden20